Clinical Observation of rhIL-2 Combined with Zhenqi Fuzheng and BaofuKang Suppository in the Treatment of Cervical Intraepithelial Neoplasia II with HPV Infection

Objective: To investigate the clinical effects of recombinant human interleu-kin-2 (rhIL-2) combined with Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. Methods: There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinp-rep cytologic test (TCT), human papilloma virus (HPV) quantitative exami-nation and colposcopy biopsy were reviewed. Results: After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical


Introduction
Cervical cancer is a serious disease threatening to human health, and many studies have demonstrated that cervical cancer and cervical intraepithelial neoplasia (CIN) (including CINI, CINII, CINIII) are infected by HPV. It is essential for persistent infection with high-risk HPV subtypes [1]. Over 80% of sexually active women would have been infected with HPV at some point by the age of 50 [2], although more than 90% of these infections are transient, and are cleared by people immune response within 6 -18 months [3]. Even when low-grade cervical intraepithelial neoplasia (CIN1) develops, the majority of these lesions regress spontaneously back to normal, particularly in young women [4]. While they have cervical CIN, in terms of CINII, CINIII, most of them will be treated with cervical conization and physical lesion, such as cold knife conization (CKC), large loop excision of the transformation zone (LLETZ), hysteroscopic conization of cervix and laser conization and so on [5]. Moreover, postoperative complications, such as wound bleeding, infection, cervical incompetence and cervical adhesions, will affect future fertility, and the cost is high. Moreover, there is a trend of rejuvenation at present, coupled with the Beijing metropolitan area of late marriage and late childbearing, the increase in the number of Advanced Maternal Age, especially in women of reproductive age. Meta-analyses [6] [7] and large retrospective linkage studies [8] [9] suggest that the excisional methods of treatment also increase the risk of preterm birth, low birth weight, premature rupture of membranes, and perinatal mortality in subsequent pregnancies; cervical intraepithelial neoplasia itself and other confounders may contribute to that risk. [10] [11] [12]. In addition, the recurrent infection of HPV and CIN may be persistent or relapse after operation, but the cervix cannot be operated many times. Therefore, it is very crucial how to treat the HPV positive patients with CIN safely and effectively, and, how to treat relapses with low cost and easy acceptance.  [14]. A study by Ramos et al. [15] demonstrated that IFN-α-treated patients with CIN III and with tumor regression expressed more type 1 T helper (Th1)-profile cytokines (IFN-γ, Tumor necrosis factor (TNF)-α, interleukin (IL)-2), with a significant reduction in the high-risk HPV viral load in the lesions. Patients whose therapy failed were smokers and had a higher expression of Th2-type (IL-4) or regulatory T cytokines (transforming growth factor (TGF)-β2 and TGF-β3).
Interleukin-2 is a member of the chemokine family of cytokines and is cur-

Materials
General Data Review-Beijing Tongren Hospital from January 2015 to December 2018-Cervical smear TCT abnormal or normal, but HPV positive patients → colposcopy directed cervical biopsy → pathological report → inclusion. Inclusion criteria: 1) colposcopic biopsy was performed in patients with HPV infection; 2) all patients in the treatment group received IL-2 treatment voluntarily; 3) age of the subjects ranged from 20 -40 years. Exclusion criteria: 1) trichomonas, mold, chlamydia, bacterial vaginosis, any one of the infections; 2) severe hypotension, severe cardiac and renal insufficiency, high fever, epilepsy; 3) pregnant or nursing women; 4) those allergic to biological agents; 5) patients with CINI or CINIII; 6) patients who had unprotected sex and couldn't be followed up on time; 7) exclusion from patients who were not followed up and change the treatment plan. Colposcopic biopsy confirmed CINII with high risk HPV infection in 600 patients according to age. Based on the principle of matching, TCT and HPV abnormalities were divided into Control group 300, Test group 300. There was no significant difference between the two groups in age and TCT (P > 0.05). As shown in Table 1. Open Journal of Obstetrics and Gynecology

Colposcopy and Cervical Biopsy
Patients who are positive for either TCT or HPV or both take some test and pay attention to some matters, such as blood routine test, leucorrhea test, and no sexual activity or vaginal medication 48 hours before colposcopy examination. If abnormal images were found under colposcopy, biopsy was taken at the site. If no abnormal images were found, biopsy was taken at 3, 6, 9, 12 points of cervix. Meanwhile, endocervical curettage (ECC) was taken and tissue of this was sent for biopsy too. IL-2 one million units + 2 ml sterile water for injection, subcutaneous injection, once a day, for 2 weeks every month, as a course of treatment. After half a month interval, the next course of treatment was carried out, which is performed for 3 courses. Zhenqi Fuzheng Capsule is taken 6 capsules at a time, twice a day, orally. The course of treatment is two weeks. After half a month interval, the next course of treatment was carried out, which is performed for 3 courses. Baofukang suppository: is applied to patient by two pills to the vagina every night for 8 days in a month, which is performed for 3 courses.

Observation Index
1) General condition: observe the change of clinical symptoms and subjective Open Journal of Obstetrics and Gynecology feeling of patients before and after taking medicine, and examine the body carefully; 2) if there is any adverse reaction, deal with the symptoms; 3) the TCT and HPV quantitative tests were reexamined after 4 months; 4) a colposcopic biopsy of the person who is positive for either one or both of the re-examinations is done, and treatment is changed mid-course.

Evaluation
HPV DNA would be tested after patients had been treated for three sessions to evaluate the drugs effectiveness. Cure: HPV turns negative; Effective: HPV Ratio Drops by 2/3; Ineffective: Ratio unchanged or increased. Total effective rate is cure + effective/total%. Negative conversion rate of HPV. Negative rate: HPV negative number/total number of cases 100%, cervical lesions cure rate: cure number/total number of cases 100%.

Statistical Analysis
SPP20.0 was used for statistical analysis, the data expressed by ( x ± s) and t test was used for comparison among groups. Differences between groups of the count data were evaluated by the Chi-square test, p < 0.05. It was significant difference of p < 0.05.

Follow-Up Results
During the follow-up period of 3 months, 3 patients had local injection pain and 2 patients had occasional low fever, which did not exceed 38˚C. In the control group, 2 cases lost follow-up and 2 cases changed treatment plan, while in the experimental group, 3 cases changed other treatment because they could not stand the local pain caused by injection.

Comparison of HPV Negative Conversion Rate between Two Groups
After 3 months, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (χ 2 = 36.774, p = 0.000), as shown in Table 2.

Comparison of Cure Rate of Cervical Lesion between Two Groups
After 3 months of treatment, the curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The difference between the two groups was statistically significant (χ 2 = 38.430, p = 0.000), as shown in Table 3.

Discussion
Cervical cancer (CC) is the third most common cancer in women worldwide accounting for 13% of all female cancers in developed countries. Persistent infection with HPV is considered the major cause of CC [16] [17] [18] [19]. Most sexually active women will have an HPV infection at some time in their life, with or without low intraepithelial lesions (LSIL), which will be spontaneously cleared by the immune system. However, in a small proportion of women the virus is able to establish a persistent infection, probably due to the synergistic effect of suboptimal host-dependent immune response and HPV-induced immunological changes, and may cause a different clinical outcome [20] [21] [22]. Escape from innate immune recognition seems to be the hallmark of HPV pathogenesis. Failure to develop an effective cell-mediated immune response results in persistent infection and increased risk of malignant transformation of the cervical cells [23] [24]. Interleukin 2 (IL-2) has been used to treat diverse types of cancer that express the IL-2 receptor (IL-2R) such as intestinal cancer [25] [26], esophageal cancer [27], and head and neck cancer [28]. The expression of IL-2R in cervical cancer cells has been reported by some groups and by our research group [29] [30]. On the other hand, IL-2R is present in normal cells of the immune system, for example, lymphocytes [31], natural killer cells [32], and dendritic cells [33]. Studies demonstrate that treatment with 100 IU of IL-2 induces a decrease in the phosphorylation of JAK3 and STAT5 proteins involved in the proliferation of cervical cancer cells [34]. In addition, the precancerous lesion of cervical cancer is cervical intraepithelial neoplasia (CIN). Its pathological diagnosis is divided into three levels, namely, CINI, II and III. 70% -80% of CIN II and III can develop into carcinoma in situ and invasive cancer, so all CIN II and CINIII should be treated [35] [36] [37]; however, for young and unborn patients, the residual lesions or recovery after physical treatment or LEEP, cold knife conization and other surgical treatment are not excluded Reoperation may be the most important factor affecting the delivery. Cervical scar is not conducive to the expansion The results showed that rhIL-2 combined with Zhenqifuzheng and Baofukang suppository was superior to Zhenqifuzheng and Baofukang suppository in the treatment of cervical CINII combined with HPV infection. However, this is slightly lower than the therapeutic effect of rhIL-2 and cervical circumcision in the treatment of CINI combined with HPV infection [39] [40]. However, this treatment plan avoids the invasive treatment of LEEP, the abortion and premature delivery caused by cervical dysfunction after operation, or the difficulty of delivery caused by cervical scar formation, which increases the chance of cesarean section. In addition, it is also effective for recurrent patients and patients with persistent HPV infection. Only immunotherapy alone can cure most of the patients with HPV infection and CINII combined with HPV infection. The reasons may be as follows: 1) rhIL-2 is a kind of lymphokine, which can induce cytotoxic T cells, natural killer cells and lymphokine activated killer cells (LAK) to increase in value, enhance its killing activity, and then clear the tumor cells in vivo, also can enhance the secretion of antibody and interferon, with the functions of anti-tumor, anti-virus infection, antibacterial infection and improving immunity; 2) It is the core substance of the immune response of the body, and it is an immunomodulator [41] [42]; 3) Zhenqi Fuzheng can significantly increase CD3+, CD4+ T, CD4+/CD3+ ratio, enhance the activity of NK cells, improve the cellular and humoral immune functions of the body, and play an anti-tumor role [43].

Conclusion
In a word, it has an essential clinical value that cervical intraepithelial neoplasia II associated with HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied. Moreover, the reason why the therapeutic effect is not more than 90%, has to be further analyzed, whether it is related to age, sexual partner, condom use and menstruation and so on. In addition, during the outbreak of the novel coronavirus, in order to cut down hospital admissions, decrease the number of patients coming back to the hospital, and reduce patient aggregation and cross-infection, patients were performed a colposcopy biopsy in outpatient, and were prescribed drugs for treatment of cervical lesions for three months based on the colposcopy results, and have achieved satisfactory results.